Perfusión contínua de ceftolozano/tazobactam alcanza niveles terapéuticos CMI>4mg/L durante más tiempo comparado con su adm intermitente Importante en fármacos Tpo dependientes https://t.co/IhmngFEmZD @Farm_Torrecard
RT @Theriaque_CNHIM: Continuous infusion of #ceftolozane / #tazobactam is associated with a higher probability of target attainment in pati…
Continuous infusion of #ceftolozane / #tazobactam is associated with a higher probability of target attainment in patients infected with #Pseudomonas aeruginosa - PubMed - NCBI https://t.co/T0AJDzWb3C
Continuous infusion of ceftolozane/tazobactam is associated with a higher probability of target attainment in patients infected with Pseudomonas aeruginosa https://t.co/wIRABcUHGC
Continuous infusion of ceftolozane/tazobactam is associated with a higher probability of target attainment in patients infected with Pseudomonas aeruginosa https://t.co/Nozvl7L6cM
Continuous infusion of ceftolozane/tazobactam is associated with a higher probability of target attainment in patients infected with Pseudomonas aeruginosa https://t.co/c5eUqggn7K
Continuous infusion of ceftolozane/tazobactam is associated with a higher probability of target attainment in patients infected with Pseudomonas aeruginosa. https://t.co/c3lygPzBER